Prosecution Insights
Last updated: August 17, 2026
Application No. 18/520,315

ORGANIC METAL COMPLEX AND ORGANIC LIGHT EMITTING ELEMENT

Non-Final OA §102
Filed
Nov 27, 2023
Priority
Nov 28, 2022 — JP 2022-189150 +1 more
Examiner
O DELL, DAVID K
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Canon Inc.
OA Round
1 (Non-Final)
58%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
776 granted / 1345 resolved
-2.3% vs TC avg
Strong +36% interview lift
Without
With
+36.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
40 currently pending
Career history
1396
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
34.6%
-5.4% vs TC avg
§102
14.4%
-25.6% vs TC avg
§112
30.1%
-9.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1345 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION 1. Claims 1-17 are pending in the current application. 2. This application has JAPAN 2022-189150 11/28/2022 JAPAN 2023-114990 07/13/2023. Response to Restriction Election 3. Applicant’s election of group I and the species, compound A-13 PNG media_image1.png 196 171 media_image1.png Greyscale , in the reply filed on June 4, 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)). Applicants’ representative fails to state which claims read on the elected species, which could be held non-responsive, however the examiner has determined that claims 1, 3, 5-8 read on the species. As detailed in the following rejections, the generic claim encompassing the elected species was not found patentable. The search and examination was continued until prior art was found that anticipated or rendered obvious a non-elected species that falls within the scope of the generic Markush claim reading on the elected species. As per MPEP 803.02 II. C. “[T]he examiner must continue to search the species of the claim unless the claim has been found to be unpatentable over prior art.” The examiner “need not continue to search the claim if the claim is rejected over prior art”. [ibid. D.] Therefore, the search and examination is restricted to the claims reading on the elected species, and claims not reading on the elected species are held withdrawn. Accordingly, claims 2 and 4 which do not read on the elected species are withdrawn. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 4. Claim(s) 1, 5-8 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Lee EP 3715437. Lee on pages 32-33 teaches compounds 24, 31 and 32: PNG media_image2.png 170 183 media_image2.png Greyscale PNG media_image3.png 138 174 media_image3.png Greyscale PNG media_image4.png 155 179 media_image4.png Greyscale These compounds read on Formula One of claim 1 wherein M is Ir, L is the derivative 3 where R 40 and R 42 are alkyl, R 41 is H, m is 1, p is 2, R20 and 2R22 are methyl, R10 and R14 are H, F, or aryl, R7 is F, and all the other Rs are H, and n is 0. Objections 5. Claim 3 is objected to for depending from a rejected base claim, but would be allowable in independent format with all the limitations of the base claim and any intervening claim. Allowable Subject Matter 6. The following is a statement of reasons for the indication of allowable subject matter: The closest prior art is Lee as cited above. The differs from the compounds of claim 3 by the ring fusion with the variable X. There is no teaching suggestion motivation or explanation in the prior art that would lead one to a ring fused analog at these positions. Conclusion 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID K O'DELL whose telephone number is (571)272-9071. The examiner can normally be reached on Monday - Friday 9:30 - 7:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached on 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated- interview-request-air-form. /DAVID K O'DELL/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Nov 27, 2023
Application Filed
Jul 16, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12703687
TETRAHYDROISOQUINOLINE COMPOUND AS POTASSIUM CHANNEL MODULATOR AND PREPARATION AND APPLICATION THEREOF
4y 1m to grant Granted Aug 11, 2026
Patent 12698265
PLANT EXTRACTS ENRICHED WITH IPOLAMIIDE DERIVATIVES AS IMMUNOSUPPRESSANTS FOR TREATING IMMUNOLOGICAL DISORDERS
6y 11m to grant Granted Aug 04, 2026
Patent 12686685
METHOD FOR LARGE-SCALE SYNTHESIS OF TETRODOTOXIN
3y 6m to grant Granted Jul 21, 2026
Patent 12686683
TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF
11m to grant Granted Jul 21, 2026
Patent 12679855
INHIBITORS OF THE ENZYME ENOLASE FOR PRECISION ONCOLOGY
4y 11m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
58%
Grant Probability
94%
With Interview (+36.0%)
2y 9m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1345 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month